Pharma Preps Legal Strategy Against New US Drug Pricing Regulation

The US Senate’s newly passed drug pricing regulation will allow Medicare to cut the prices of a select number of drugs over the course of the decade. In response, pharma companies have begun prepping their legal objections to the rule. The industry will likely sue the Center for Medicare and Medicaid Service (CMS) as regulations begin, affect the rulemaking deliberations, and shift the price negotiation process in its favor.

According to Fraiser Kansteiner, “None of this should come as a shock, she added, citing the pharma industry’s historical litigiousness when it comes to “even the most moderate price transparency laws.” The industry has a long history of leveraging patent thickets, pay-for-delay agreements, product hopping and more to keep hold of their product monopolies.”

To read more, click here.

(Source: Fierce Pharma, August 11th, 2022)